 |
|
|
| |
In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule
capsid assembly modulator, for the treatment of chronic hepatitis B
|
| |
| |
EASL 2018
Reported by Jules Levin
Xue Zhou1, Yuan Zhou1, Xiaojun Tian1, Fang Shen1, Guang Yang1, Wei Zhu1, Giorgio Ottaviani2, Jianxun Xie1, Hong Shen1, John A. T. Young2, and Lu Gao1
RO7049389, a core protein allosteric modulator, demonstrates robust anti-HBV activity in chronic hepatitis B patients and is safe and well tolerated - (04/18/18)
Combination treatment of a TLR7 agonist RO7020531 and a core protein allosteric modulator RO7049389 achieved sustainable viral load suppression and HBsAgloss in an AAV-HBV mouse model - (04/18/18)
HBV at EASL
|
| |
|
|
|
|
|
